All In Biotech

Drug Trial Radar · NCT06926621

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type I

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

44

Planned (sponsor's estimate)

Start

Apr 28, 2025

Primary completion

Jan 30, 2029

Study completion Jan 30, 2029

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Apr 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).

Conditions

  • Myotonic Dystrophy Type 1 (DM1)

Interventions

  • VX-670Drug

    Solution for intravenous administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 up to Week 108

Locations

16 sites in 8 countries. Site status is shown where the registry gives one.

  • St. Louis Children's Hospital - Neurology

    St Louis, Missouri

  • Wake Forest Univ School of Medicine - Neurology

    Winston-Salem, North Carolina

  • Virginia Commonwealth University - Sanger Hall

    Richmond, Virginia

  • Wesley Research Institute

    Auchenflower, Australia

  • Neuroscience Clinical Trials Unit, Alfred Brain

    Melbourne, Australia

  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Pulmonology

    Leuven, Belgium

  • Altasciences Montreal

    Montreal, Canada

  • Montreal Neurological Institute-Hospital

    Montreal, Canada

  • University of Ottawa

    Ottawa, Canada

  • Universite Laval - Neurology

    Québec, Canada

  • Friedrich Baur Institute

    München, Germany

  • Maastricht UMC

    Maastricht, Netherlands

  • Hospital Universitario y Politecnico La Fe - Neurology

    Valencia, Spain

  • Queen Elizabeth University Hospital - Neurology

    Glasgow, United Kingdom

  • Leonard Wolfson Experimental Neurology Centre CRF

    London, United Kingdom

  • Royal Hallamshire Hospital - Neurology

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.